S-1: Medline Selling Stockholders Offer 75M Class A Shares

Medline Inc. selling stockholders are offering 75 million Class A common shares, with the company receiving no proceeds from the sale.

Summary

• Medline is the largest provider of medical-surgical products and supply chain solutions, serving all points of care, based on total net sales of med-surg products.
• The company offers approximately 335,000 med-surg products through its Medline Brand (190,000 products) and Supply Chain Solutions (145,000 third-party products) segments.
• Medline operates an expansive network of 70 global distribution facilities, spanning over 29 million square feet, and an owned fleet of over 2,100 MedTrans trucks, enabling next-day delivery to 95% of U.S. customers.
• Net sales have grown every year since the company's inception at a compound annual growth rate (CAGR) of 18%, and approximately 13% over the past 10 years, with nearly 90% of this growth being organic.
• Approximately 90% of Medline Brand net sales were recurring for the year ended December 31, 2025.
• The business has demonstrated resilience, growing approximately 17% during the 2008-2009 financial crisis and at an 11% CAGR during the 2020-2022 COVID-19 pandemic.
• For the year ended December 31, 2025, Medline generated net sales of $28.4 billion, net income of $1.2 billion, and Adjusted EBITDA of $3.5 billion.
• The net income margin for 2025 was 4.1%, and the Adjusted EBITDA Margin was 12.2%.
• The Medline Brand segment contributed 48.3% of total net sales and 80.6% of Segment Adjusted EBITDA in 2025, while the Supply Chain Solutions segment contributed 51.7% of total net sales and 19.4% of Segment Adjusted EBITDA.
• The company maintains a greater than 98% average Prime Vendor retention rate over the past five years and has signed new Prime Vendor agreements representing approximately $8 billion of annual contract value over the past six years.
• As of December 31, 2025, Medline had over 1,600 Prime Vendor relationships, representing $18.0 billion of net sales.
• Global inventory stood at $4.8 billion as of December 31, 2025, supporting 99% service levels, and the company has invested $1.4 billion in its distribution network over the last five years, with 25% excess capacity.
• The U.S. commercial team comprises approximately 4,000 people, with a salesforce retention rate exceeding 85% in 2025.
• Total new customer signings amounted to approximately $2.4 billion in estimated annual contract value for the year ended December 31, 2025.
• The estimated total addressable market (TAM) is approximately $375 billion globally, with $175 billion in the U.S. and $200 billion internationally.
• International net sales represented only 6.9% of total net sales for the year ended December 31, 2025.
• A potential incremental gross profit opportunity of approximately $1.3 billion exists if $5.0 billion in net sales from Supply Chain Solutions products to existing Prime Vendor customers were converted to like-for-like Medline Brand products, assuming historical margins.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal for Medline's market presence and liquidity for existing shareholders, despite the company not receiving direct proceeds from this secondary offering. The strong historical financial performance and clear growth strategy underpin a favorable outlook, though the significant control by Designating Stockholders and substantial TRA liability warrant careful consideration.

Positives

• Consistent net sales growth every year since inception (18% CAGR) and 13% over the past 10 years, with nearly 90% organic growth, demonstrating a robust business model.
• Proven resilience during economic downturns and global healthcare crises, including 17% growth during the 2008-2009 financial crisis and an 11% CAGR during the 2020-2022 COVID-19 pandemic.
• Strong market leadership as the largest provider of medical-surgical products and supply chain solutions across all points of care.
• High customer loyalty, evidenced by a greater than 98% average Prime Vendor retention rate over the past five years and $8 billion in new Prime Vendor contract value over six years.
• Significant opportunity for incremental gross profit of approximately $1.3 billion through the conversion of Supply Chain Solutions products to higher-margin Medline Brand products.
• Substantial investments in infrastructure, including $1.4 billion in the distribution network over five years, resulting in 70 global distribution centers, a large truck fleet, and 25% excess capacity for future growth.
• Strong financial performance in 2025 with $28.4 billion in net sales and $3.5 billion in Adjusted EBITDA.
• Continuous product innovation, with over 250 new products launched in the last three years and a portfolio of over 2,300 granted patents.
• Strategic partnership with Microsoft to leverage AI for supply chain resiliency and integrated inventory management.
• A customer-centric culture and recognition as a preferred employer, contributing to a U.S. salesforce retention rate greater than 85% in 2025.

Negatives

• The company will not receive any proceeds from the sale of 75,000,000 Class A common shares by the selling stockholders in this offering.
• Designating Stockholders (Blackstone, Carlyle, H&F, and the Mills Family) will collectively retain approximately 61.7% of the combined voting power, which may lead to interests conflicting with those of other stockholders.
• The company has a substantial estimated aggregate noncurrent liability of approximately $12.107 billion under the tax receivable agreement (TRA) if all Common Units were hypothetically exchanged, generally payable over a 15-year period, which could negatively impact liquidity.
• The market price of Class A common stock may be volatile or decline regardless of operating performance, influenced by various external factors.
• Lock-up restrictions applicable to the company and selling stockholders were released for this offering and may be waived again in the future, potentially increasing market supply and adversely affecting the stock price.
• Affiliates of Blackstone and Carlyle are underwriters in this offering and beneficially own over 10% of the company's common stock, and will receive over 5% of the net proceeds, creating a conflict of interest under FINRA Rule 5121.
• While Medline Brand conversion offers higher margins, it typically results in a negative impact on net sales if volume is constant due to lower average prices for Medline Brand products compared to third-party alternatives.

Risks

• Reliance on the proper function, security, and availability of information technology systems and data, as well as those of third parties throughout the global supply chain, and the impact of breaches or disruptions.
• Inherent risks associated with global operations.
• Exposure to extensive and complex laws and governmental regulations, with potential for adverse regulatory actions.
• Compliance with environmental, health, and safety requirements, and risks associated with hazardous substances in operations.
• Potential inability to fully realize anticipated benefits from existing or future acquisitions, joint ventures, investments, dispositions, or other strategic transactions.
• Adverse effects on the business, results of operations, and financial condition due to consolidation in the healthcare industry.
• Significant impact on results of operations from foreign currency exchange rate fluctuations.
• Adverse effects on profitability and cash flows from inflationary pressures.
• Uncertain global and domestic macro-economic and political conditions.
• Operating in a highly competitive industry with accelerating pricing pressure and changes in technology.
• Failure to comply with anti-corruption laws or trade restrictions, including economic sanctions.
• Inability to attract, develop, and retain key employees.
• Substantial indebtedness could adversely affect financial condition, operational flexibility, ability to react to changes, fulfill obligations, and divert cash flow for debt payments.
• Designating Stockholders will continue to hold a significant percentage of stock, and their interests may conflict with those of other stockholders.
• The market price of Class A common stock may be volatile or decline regardless of operating performance.
• Underwriters may waive lock-up restrictions in the future, which could adversely affect the price of Class A common stock.
• Medline Inc. is a holding company dependent on distributions from Medline Holdings to pay taxes, make payments under the tax receivable agreement, and pay any dividends.
• Payments under the tax receivable agreement could be substantial and have a negative impact on liquidity.
• Decisions made by pre-IPO owners may influence the timing and amount of payments received under the tax receivable agreement.
• Forum selection provisions in the amended and restated certificate of incorporation could limit stockholders' ability to obtain a favorable judicial forum for disputes.
• Conflicts of interest provisions in the amended and restated certificate of incorporation renounce certain business opportunities for Sponsors and the Mills Family.
• Restrictive covenants in debt agreements may limit the ability to pursue business strategies and comply with obligations.
• Potential for quality problems, recalls, and product liability claims.
• Impact of climate change and related legal, regulatory, and market measures.
• Aspirations, goals, and disclosures related to ESG and sustainability matters.
• Unfavorable outcome of legal proceedings.
• Ability to comply with laws and regulations relating to reimbursement of healthcare goods and services.
• Ability of the company and third parties to reduce expenses if prices for goods and services decrease.
• Adequacy of the insurance program to cover future losses.
• Ability to obtain, maintain, protect, and enforce intellectual property rights.
• Dependence on positive perceptions of the company's reputation.
• Exposure to financial risks associated with interest rate fluctuations on variable rate debt.

Future Outlook

Medline expects to continue growing in excess of the broader med-surg market, driven by increasing healthcare utilization, customer expansion into new sites, and further consolidation of med-surg spend with Medline. The company plans to achieve this through new Prime Vendor relationships, increased Medline Brand adoption, channel expansion, continuous product innovation, selective M&A opportunities, and scaling its international footprint. National health expenditures in the U.S. are projected to grow at an annual rate of 5.6% from 2023 to 2032, outpacing GDP growth, providing a favorable market backdrop. International markets, currently representing only 6.9% of net sales, offer a significant $200 billion addressable market for expansion. Operational execution and scaling are anticipated to further expand margins over time.

Management Comments

• Our mission is to make healthcare run better by delivering improved clinical, financial, and operational outcomes.
• We have grown our net sales every year by retaining existing customers while gaining share with new and existing customers, with CAGRs of 18% since our founding and approximately 13% over the past 10 years.
• Nearly 90% of our growth during the past 10 years has been organic.
• Our business is uniquely resilient during market downturns, as evidenced by our growth through every recession since our founding and during global healthcare crises.
• Not only does our business have a strong track record of results, but we also see significant runway for future sales and earnings growth.
• Our employees are committed to deeply understanding how our customers operate, what challenges they face, and how Medline can better support them.
• We focus on problem solving across the continuum of care and we deploy a team of dedicated customer success representatives to learn the complex needs of our customers.
• Our creative and collaborative culture consistently earns Medline recognition as a preferred employer.
• We are committed to delivering products of the highest standard, which is reflected by our robust quality team of over 2,700 employees.
• Challenging our team to listen intently to customers pain points and thoughtfully craft product innovation solutions has been a critical growth lever and retention driver for our business.
• We have successfully launched more than 250 new products over the last three years and will continue to innovate as a trusted thought partner to our customer base.
• Our relentless scrutiny on our own costs both in our manufacturing and distribution networks helps us to deliver quality products cost effectively.

Industry Context

StockSavvy.ai notes that Medline operates in a resilient healthcare market, with U.S. healthcare spending increasing annually for the past sixty years and projected to grow at 5.6% annually from 2023-2032, outpacing GDP. The company's integrated manufacturing and distribution model, coupled with its Prime Vendor strategy, positions it well to capitalize on industry trends such as margin pressure on providers, the shift of procedures to lower-cost care settings, and ongoing healthcare consolidation. Medline's partnership with Microsoft for AI-generated supply chain insights demonstrates an embrace of technological advancements to address supply chain resiliency, a critical industry need highlighted by recent disruptions. The significant international market opportunity ($200 billion) and Medline's relatively low international sales (6.9% of total net sales in 2025) suggest substantial untapped growth potential compared to its established U.S. presence.

Comparison to Industry Standards

• Medline is positioned as the 'largest provider of medical-surgical products and supply chain solutions serving all points of care,' based on its 2025 net sales relative to publicly reported net sales of competitors that are both med-surg manufacturers and distributors.
• The company's 18% CAGR since founding and 13% over the past 10 years, with 90% organic growth, demonstrates superior performance compared to general industry growth rates, especially given its resilience during economic downturns (17% growth during 2008-2009 financial crisis and 11% CAGR during 2020-2022 COVID-19 pandemic).
• A greater than 98% average Prime Vendor retention rate over the past five years highlights exceptional customer loyalty and a strong competitive advantage in its core distribution model, likely exceeding industry averages for similar long-term contracts.
• The identified $1.3 billion incremental gross profit opportunity from converting Supply Chain Solutions products to Medline Brand products indicates a significant internal efficiency and margin improvement potential, a strategic advantage over competitors reliant solely on third-party distribution.
• Medline's investment of $1.4 billion in its distribution network over the last five years and its reported 25% excess capacity position it favorably against competitors, suggesting a robust and scalable infrastructure capable of supporting future market demand.
• The U.S. salesforce retention rate of greater than 85% in 2025 suggests a stable and experienced commercial team, which is a competitive asset in an industry reliant on strong customer relationships.

Management Changes

Corporate Governance

Legal Proceedings

• For the year ended December 31, 2025, litigation (gains) charges, net, amounted to $(33) million, which included a settlement adjustment of $(8) million related to EtO litigation, $(43) million related to settlement of an intellectual property dispute, and $18 million related to other legal settlements.
• For the year ended December 31, 2023, litigation (gains) charges, net, amounted to $161 million, which included settlement charges of $163 million related to EtO litigation and $3 million of other legal costs, net of $(5) million of insurance recoveries.

Related Party Transactions

• Director Nomination Agreements: Entered into with Blackstone, Carlyle, H&F, and the Mills Family, granting them rights to designate directors based on ownership.
• Information and Access Agreement: Entered into with Hux, allowing one non-voting observer to the board.
• Exchange Agreement: With Continuing Unitholders, allowing exchange of Common Units for Class A common stock on a one-for-one basis.
• Registration Rights Agreement: With Principal Stockholders and Other Pre-IPO Investors, providing customary demand and piggyback registration rights.
• Tax Receivable Agreement: Entered into with certain pre-IPO owners, providing for payments of 90% of certain tax benefits realized by Medline Inc.
• Services Agreements: With Blackstone Management Partners L.L.C., Blackstone Capital Partners VIII L.P., Carlyle Investment Management L.L.C., Hellman & Friedman LP, and Mozart Holdco, Inc. for monitoring and evaluation services. Payments made in 2023 ($360k to BX, $244k to Carlyle), 2024 ($711k to BX, $120k to H&F), and 2025 ($887k to BX, $60k to Carlyle, $555k to H&F).
• Loans to Andrew Mills: Andrew Mills, a director, received an allocation of term loans under Senior Secured Credit Facilities. As of December 31, 2025, $17.6 million principal remained outstanding. In 2025, $0.2 million in principal and $1.5 million in interest were paid.
• Underwriting of IPO: Blackstone Securities Partners L.P. and TCG Capital Markets L.L.C. (affiliates of Blackstone and Carlyle) underwrote shares in the IPO, creating a conflict of interest under FINRA Rule 5121.
• Family Relationships: Charles Mills (Chair) is cousin of Andrew Mills (Director). James Abrams (former COO and director) is brother-in-law of Andrew Mills and brother of William J. Abrams (EVP, Supply Chain Solutions). Justin Mills (sales representative) is son of Andrew Mills. Robert Abrams (Corporate Purchasing Director) is father of James Abrams and William J. Abrams.
• MPU Rollover Investments: Several Named Executive Officers (James Boyle, Michael Drazin, James Pigott, William J. Abrams, Amanda Laabs, Alex Liberman, Doug Golwas) reinvested Liquidity Event MPU Amounts into Class A Units and/or CUPIs in 2021, some funded by loans from Medline Holdings. All loans were fully repaid as of October 20, 2023.

Stakeholder Impact

• Shareholders: Selling stockholders benefit from increased liquidity for their holdings. New investors gain access to a leading company in the healthcare sector. Existing public shareholders may experience potential share price volatility due to increased supply from the secondary offering and the release of lock-up restrictions. The significant voting power of Designating Stockholders could limit the influence of other shareholders.
• Employees: The executive compensation program, including base salary, annual incentive bonuses, and long-term equity incentives, is designed to attract, retain, and motivate talent. Employee benefit programs, including 401(k) with matching contributions and health benefits, are provided. The company's growth strategy could create further opportunities for employees.
• Customers: Benefit from Medline's integrated business model, high-quality Medline Brand products, cost savings, efficient supply chain, and clinical education programs. The Prime Vendor model aims to simplify procurement and deliver superior service levels and value.
• Suppliers: Third-party product suppliers gain access to Medline's scaled platform and large, diverse customer base, ensuring reliable delivery of their products.
• Creditors: The company's substantial indebtedness and restrictive covenants in debt agreements impact its financial flexibility. The repayment of debt using IPO proceeds is positive for creditors, but the ongoing TRA liability represents a significant future obligation.

Next Steps

• Underwriters expect to deliver the shares of Class A common stock against payment on or about the specified closing date in 2026.
• The company plans to continue growing with its Prime Vendor customers, winning new Prime Vendor customers, and increasing Medline Brand adoption among non-Prime Vendor customers.
• Ongoing strategies include continuous product innovation, channel expansion (e.g., animal health, dental), international expansion, and disciplined M&A execution.
• The Compensation Committee expects to grant time-based Restricted Stock Units (RSUs) to participating Named Executive Officers in the first quarter of 2026 for their 2025 Awards.
• Beginning in 2026, independent non-employee directors will receive an annual equity award of RSUs.

Key Dates

Recommendation

Medline demonstrates strong market leadership, consistent organic growth, and a resilient business model in the stable healthcare sector. The company's strategic investments in its distribution network and product innovation, coupled with high customer retention, are significant positives. However, the current filing is a secondary offering where the company receives no proceeds, and the substantial influence of Designating Stockholders, along with the large Tax Receivable Agreement liability, introduce complexities and potential conflicts of interest that warrant a cautious 'hold' stance for new investors. Existing investors should monitor the impact of the increased share float and the ongoing influence of major shareholders.

Keywords

Medical-surgical products, Supply chain solutions, Healthcare distribution, Medline Brand, Prime Vendor model, Adjusted EBITDA, S-1 registration, Secondary offering, Class A common stock, Corporate governance, Risk management, Financial performance, Healthcare industry, Distribution network, Product innovation, Mergers and acquisitions, International expansion, Tax receivable agreement, Private equity, Blackstone, Carlyle, Hellman & Friedman